 |
|
|
| |
Efficacy and Safety of Dolutegravir Relative to Commonly-Used 3rd-Agents at 96 Weeks in Treatment-Naive HIV-1-Infected Patients: A Systematic Review and Network Meta-analysis
|
| |
| |
Reported by Jules Levin
20th International AIDS Conference; July 20-25, 2014; Melbourne, Australia
Dipen A. Patel,1 Sonya J. Snedecor,1 Wing Yu Tang,1 Lavanya Sudharshan,1 Jessica W. Lim,2 Robert Cuffe,3 Sonia Pulgar,4 Kim A. Gilchrist,5 Rodrigo Refoios Camejo,6 Jennifer Stephens,1 Garrett Nichols7
1Pharmerit International, Bethesda, MD, USA; 2GlaxoSmithKline, Stockley Park, UK; 3ViiV Healthcare, Middlesex, UK; 4Becton Dickinson, Franklin Lakes, NJ, USA (GSK employee at time of research); 5GlaxoSmithKline, Renaissance, PA, USA; 6GlaxoSmithKline, Brentford, UK; 7GlaxoSmithKline, Research Triangle Park, NC, USA
|
| |
|
|
|
|
|
